Treatment and practical considerations of diabetic kidney disease

被引：5
作者：
Bilen, Yara [1 ]
Almoushref, Allaa [2 ]
Alkwatli, Kenda [3 ]
Osman, Omar [2 ]
Mehdi, Ali [2 ]
Sawaf, Hanny [2 ]
机构：
[1] Cleveland Clin, Dept Internal Med, Cleveland, OH USA
[2] Cleveland Clin, Dept Kidney Med, Cleveland, OH 44195 USA
[3] Cleveland Clin, Dept Endocrinol, Cleveland, OH USA
来源：
FRONTIERS IN MEDICINE | 2023年 / 10卷
关键词：
diabetes; diabetic nephropathy; diabetic kidney disease; chronic kidney disease; SGLT2; inhibitor; finerenone; GLP-1 receptor agonist; COTRANSPORTER; 2; INHIBITORS; CARDIOVASCULAR OUTCOMES; SGLT2; HEART-FAILURE; BLOOD-PRESSURE; NADPH OXIDASE; TYPE-2; NEPHROPATHY; ALBUMINURIA; FINERENONE;
D O I：
10.3389/fmed.2023.1264497
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Diabetic kidney disease (DKD) is a complication of diabetes that can lead to kidney failure. Over the years, several drugs have been developed to combat this disease. In the early 90s, angiotensin blockade (ACEi and ARBs) was introduced, which revolutionized the treatment of DKD. In recent years, newer drugs such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, endothelin antagonists, and mineralocorticoid receptor antagonists (MRA) have shown great promise in reducing albuminuria and protecting the kidneys. These drugs are being used in combination with lifestyle modifications, patient education, and risk factor modification to effectively manage DKD. In this review, we will explore the latest pharmacological options, their efficacy, and their potential to revolutionize the management of this debilitating disease.
引用
收藏
页数：13
相关论文
共 100 条
  • [61] Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
    Mehdi, Uzma F.
    Adams-Huet, Beverley
    Raskin, Philip
    Vega, Gloria L.
    Toto, Robert D.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (12): : 2641 - 2650
  • [62] Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
    Mulder, Skander
    Heerspink, Hiddo J. L.
    Darshi, Manjula
    Kim, Jiwan J.
    Laverman, Gozewijn D.
    Sharma, Kumar
    Pena, Michelle J.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (11) : 2422 - 2428
  • [63] Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
    Muskiet, Marcel H. A.
    Tonneijck, Lennart
    Huang, Yao
    Liu, Minzhi
    Saremi, Aramesh
    Heerspink, Hiddoj L.
    van Raalte, Daniel H.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (11) : 859 - 869
  • [64] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
    Neal, Bruce
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    de Zeeuw, Dick
    Fulcher, Greg
    Erondu, Ngozi
    Shaw, Wayne
    Law, Gordon
    Desai, Mehul
    Matthews, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) : 644 - 657
  • [65] Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence
    Neuhofer, W.
    Pittrow, D.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 : 50 - 67
  • [66] Pregnancy in pulmonary arterial hypertension
    Olsson, Karen M.
    Channick, Richard
    [J]. EUROPEAN RESPIRATORY REVIEW, 2016, 25 (142) : 431 - 437
  • [67] A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin
    Onishi, Akira
    Fu, Yiling
    Patel, Rohit
    Darshi, Manjula
    Crespo-Masip, Maria
    Huang, Winnie
    Song, Panai
    Freeman, Brent
    Kim, Young Chul
    Soleimani, Manoocher
    Sharma, Kumar
    Thomson, Scott Culver
    Vallon, Volker
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2020, 319 (04) : F712 - F728
  • [68] The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
    Parving, HH
    Lehnert, H
    Bröchner-Mortensen, J
    Gomis, R
    Andersen, S
    Arner, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 870 - 878
  • [69] Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
    Perkovic, V.
    Jardine, M. J.
    Neal, B.
    Bompoint, S.
    Heerspink, H. J. L.
    Charytan, D. M.
    Edwards, R.
    Agarwal, R.
    Bakris, G.
    Bull, S.
    Cannon, C. P.
    Capuano, G.
    Chu, P. -L.
    De Zeeuw, D.
    Greene, T.
    Levin, A.
    Pollock, C.
    Wheeler, D. C.
    Yavin, Y.
    Zhang, H.
    Zinman, B.
    Meininger, G.
    Brenner, B. M.
    Mahaffey, K. W.
    McGuire, Darren K.
    Holman, Rury
    Home, Philip
    Scharfstein, Dan
    Parfrey, Patrick
    Shahinfar, Shahnaz
    August, Phyllis
    Chang, Tara
    Sinha, Arjun D.
    Januzzi, James
    Kolansky, Daniel
    Amerena, John
    Hillis, Graham
    Gorelick, Philip
    Kissela, Brett
    Kasner, Scott
    Lindley, Richard
    Fulcher, Greg
    Ounadjela, Souhila
    Hufert, Karina
    von Ingersleben, Gabriele
    Gaglia, Jason
    Harris, Ronald
    Hudson, Margo
    Turchin, Alexander
    Cheifetz, Adam
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) : 2295 - 2306
  • [70] Petrie JR, 2020, LANCET DIABETES ENDO, V8, P803, DOI 10.1016/S2213-8587(20)30311-9
12345678910